Core Insights - Eagle Pharmaceuticals, Inc. has released its unaudited financial statements for the three months ended March 31, 2025, which are accessible on their investor relations website [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical trials, manufacturing, and commercialization [2] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [2] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (in Japan), and BYFAVO® and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [2] - The company's oncology and CNS/metabolic critical care pipeline features product candidates aimed at addressing underserved therapeutic areas across various disease states [2] - Eagle is focused on developing medicines that could integrate into the personalized medicine paradigm in cancer care [2]

Core Points - Eagle Pharmaceuticals, Inc. announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders scheduled for October 17, 2025 [1] - The company is delivering a Notice of Internet Availability of Proxy Materials to stockholders of record as of August 18, 2025 [2] - The proxy materials, including the Notice, proxy information statement, and proxy card, are accessible online [2] - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines [3] - The company's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® [3] - Eagle's pipeline includes oncology and CNS/metabolic critical care product candidates aimed at addressing underserved therapeutic areas [3]

Core Viewpoint - Eagle Pharmaceuticals, Inc. has appointed Abhinav "Abi" Jain as an independent member of its Board of Directors, which is part of a cooperation agreement with Nantahala Capital Management, a significant shareholder holding approximately 38% of the company's outstanding shares [1][2]. Group 1: Appointment Details - Abhinav Jain will serve as a Class III director with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders [1]. - Jain will also be a member of the Board's Compensation Committee and Nominating and Corporate Governance Committee [1]. - The cooperation agreement includes provisions for the appointment of a second independent director by May 15, 2026 [1][3]. Group 2: Background of Abhinav Jain - Jain is currently an Analyst at Nantahala, focusing on investments in specialty and generic pharmaceuticals [2]. - Prior to Nantahala, he was an Associate at Angelo, Gordon & Co., where he concentrated on private equity and structured credit investments [2]. - Jain holds a degree in Chemical-Biological Engineering from the Massachusetts Institute of Technology and an M.B.A. with honors in Finance and Entrepreneurial Management from The Wharton School [2]. Group 3: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company involved in research and development, clinical, manufacturing, and commercial activities [4]. - The company is dedicated to developing innovative medicines aimed at improving patients' lives, with a portfolio that includes products like PEMFEXY®, RYANODEX®, and others [4]. - Eagle's pipeline includes oncology and critical care candidates targeting underserved therapeutic areas, with a focus on personalized medicine in cancer care [4].

Core Points - Eagle Pharmaceuticals, Inc. will hold its 2025 Annual Meeting of Stockholders on October 17, 2025 [1] - The record date for stockholders to participate in the meeting is set for August 18, 2025, at 5 p.m. Eastern Time [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial sectors [3] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [3] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [3] - The oncology and critical care pipeline includes product candidates aimed at addressing underserved therapeutic areas across multiple disease states [3] - The company focuses on developing medicines that could be integrated into the personalized medicine paradigm in cancer care [3]

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to increase the initial purchase price of each preferred share purchase right from $10.00 to $20.00, effective immediately, in response to significant dislocation in the trading price of its common stock [1][2]. Group 1: Rights Plan Details - The Rights Plan is designed to penalize any person or group acquiring 10% or more of the company's common stock without Board approval, with a higher threshold of 15% for passive institutional investors [2]. - The amendment increases the potential dilution an Acquiring Person would face if the Rights Plan is triggered, thereby protecting stockholders' long-term investment value [2]. - The Rights Plan will automatically expire on October 30, 2025, unless earlier redeemed or exchanged by the company [3]. Group 2: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial operations [4]. - The company is focused on developing innovative medicines, particularly in oncology and critical care, with products like PEMFEXY®, RYANODEX®, and others in its pipeline [4].